Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

Phylogenetic analysis of the reverse transcriptase (RT) and protease of 117 published complete human immunodeficiency virus (HIV) type 1 genome sequences demonstrated that these genes cluster into distinct subtypes. There was a slightly higher proportion of informative sites in the RT (40.4%) than in the protease (34.8%; P= .03). Although most variation between subtypes was due to synonymous nucleotide substitutions, several subtype-specific amino acid patterns were observed. In the protease, the subtype-specific variants included 7 positions associated with drug resistance. Variants at positions 10, 20, 36, and 82 were more common in non-B isolates, whereas variants at positions 63, 77, and 93 were more common in subtype B isolates. In the RT, the subtype-specific mutations did not include positions associated with anti-retroviral drug resistance. RT and protease sequences from 2246 HIV-infected persons in northern California were also examined: 99.4% of the sequences clustered with subtype B, whereas 0.6% clustered with subtype A, C, or D.

[1]  J. Coste,et al.  Human T-lymphotropic virus (HTLV) types I and II: seroprevalence among intravenous drug users in continental France. Retrovirus Study Group of the French Society of Blood Transfusion. , 1993, AIDS.

[2]  M. Otto,et al.  Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. , 1995, Antiviral research.

[3]  J. Albert,et al.  Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. , 1998, AIDS research and human retroviruses.

[4]  A. Lapedes,et al.  Timing the ancestor of the HIV-1 pandemic strains. , 2000, Science.

[5]  B. Larder,et al.  Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .

[6]  M. Nei,et al.  Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. , 1986, Molecular biology and evolution.

[7]  J. Verhoef,et al.  The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. , 1999, The Journal of antimicrobial chemotherapy.

[8]  D. Gotte,et al.  Virtually full-length subtype F and F/D recombinant HIV-1 from Africa and South America. , 2000, Virology.

[9]  B. Korber,et al.  Signature pattern analysis: a method for assessing viral sequence relatedness. , 1992, AIDS research and human retroviruses.

[10]  Guy Burtonboy,et al.  Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor , 2001, Antimicrobial Agents and Chemotherapy.

[11]  D. Swofford PAUP*: Phylogenetic analysis using parsimony (*and other methods), Version 4.0b10 , 2002 .

[12]  Martine Peeters,et al.  Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.

[13]  D. Katzenstein,et al.  Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. , 1999, AIDS research and human retroviruses.

[14]  J. Pillonel,et al.  Increasing diversity of HIV‐1M serotypes in French blood donors over a 10‐year period (1985–1995) , 1997, AIDS.

[15]  P. Sharp,et al.  Genetic diversity of HIV-1: the moving target. , 2000, AIDS.

[16]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[17]  M. Mouroux,et al.  Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor , 1999, Journal of Clinical Microbiology.

[18]  D. Katzenstein,et al.  Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe , 1997, Journal of virology.

[19]  J. Goudsmit,et al.  Circulation of subtype A and gagA/envB recombinant HIV type 1 strains among injecting drug users in St. Petersburg, Russia, correlates with geographical origin of infections. , 1999, AIDS research and human retroviruses.

[20]  E. Wolf,et al.  Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors. , 1997, AIDS.

[21]  Hideo Matsuda,et al.  fastDNAmL: a tool for construction of phylogenetic trees of DNA sequences using maximum likelihood , 1994, Comput. Appl. Biosci..

[22]  Z. Yang,et al.  Approximate methods for estimating the pattern of nucleotide substitution and the variation of substitution rates among sites. , 1996, Molecular biology and evolution.

[23]  D. Gotte,et al.  Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. , 1998, Virology.

[24]  D J Hu,et al.  Protease sequences from HIV-1 group M subtypes A–H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide , 2000, AIDS.

[25]  David L. Robertson,et al.  HIV-1 nomenclature proposal: a reference guide to HIV-1 classification. , 2000 .

[26]  G. Learn,et al.  HIV-1 Nomenclature Proposal , 2000, Science.

[27]  K. Hertogs,et al.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting , 2001 .

[28]  J. Baggs,et al.  Impact of HIV type 1 subtype variation on viral RNA quantitation. , 1999, AIDS research and human retroviruses.

[29]  R. Shafer,et al.  Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. , 2000, Journal of virological methods.

[30]  M. P. Cummings,et al.  PAUP* Phylogenetic analysis using parsimony (*and other methods) Version 4 , 2000 .

[31]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[32]  John W. Mellors,et al.  Human retroviruses and AIDS 1996. A compilation and analysis of nucleic acid and amino acid sequences , 1997 .

[33]  F. Brun-Vézinet,et al.  Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. , 1998, AIDS.

[34]  B. Korber,et al.  Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease , 1997, Journal of virology.

[35]  J. Fantini,et al.  Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. , 2001, The Journal of infectious diseases.

[36]  Soriano,et al.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. , 2001, AIDS.

[37]  D. Burke,et al.  Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. , 1995, AIDS research and human retroviruses.

[38]  D. Pieniążek,et al.  Genetic Variation and Susceptibilities to Protease Inhibitors among Subtype B and F Isolates in Brazil , 1999, Antimicrobial Agents and Chemotherapy.

[39]  P. Sharp,et al.  A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[40]  T. Leitner,et al.  Most HIV‐1 genetic subtypes have entered Sweden , 1997, AIDS.

[41]  A. Jones-Trower,et al.  Characterization and Enhanced Processing of Soluble, Oligomeric gp140 Envelope Glycoproteins Derived from Human Immunodeficiency Virus Type-1 Primary Isolates , 2001 .